You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Circulating Tumor Cells
|
|---|---|
| Published in |
Molecular Diagnosis & Therapy, August 2012
|
| DOI | 10.2165/11594520-000000000-00000 |
| Pubmed ID | |
| Authors |
Paola Gazzaniga, Cristina Raimondi, Angela Gradilone, Giuseppe Naso, Enrico Cortesi, Luigi Frati |
| Abstract |
Circulating tumor cells (CTCs) are cells of presumed epithelial origin, whose prognostic and predictive value in metastatic cancer patients has recently been demonstrated. To date, the count of CTCs through the CellSearch® system represents a valid approach for monitoring disease status in patients with metastatic colorectal, breast, and prostate cancer; in these cancer types, a rise in the CTC count at any time during treatment predicts a poor outcome. Nevertheless, the clinical utility of monitoring CTC counts remains controversial, and what to do when CTC counts rise during therapy still remains an unanswered question. In this report, we suggest how to integrate CTC counts with their molecular characterization to better translate biologic information obtained on CTCs into daily clinical practice. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 33% |
| France | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 100% |
| Student > Ph. D. Student | 4 | 80% |
| Student > Bachelor | 2 | 40% |
| Other | 1 | 20% |
| Lecturer | 1 | 20% |
| Other | 2 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 180% |
| Biochemistry, Genetics and Molecular Biology | 2 | 40% |
| Agricultural and Biological Sciences | 2 | 40% |
| Nursing and Health Professions | 1 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 20% |
| Other | 1 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2022.
All research outputs
#5,956,880
of 22,663,150 outputs
Outputs from Molecular Diagnosis & Therapy
#65
of 373 outputs
Outputs of similar age
#38,198
of 149,501 outputs
Outputs of similar age from Molecular Diagnosis & Therapy
#14
of 54 outputs
Altmetric has tracked 22,663,150 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 373 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 149,501 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.